Onswik is a newly approved weekly insulin for adults with type 2 diabetes. It supplies basal insulin, the background insulin needed between meals and overnight. That could mean far fewer insulin injections over a year. Blood sugar checks and a prescriber's plan still matter.
For someone already using weekly tirzepatide or semaglutide, the shared schedule can be confusing. These medicines do different jobs. Onswik supplies insulin directly; the others work through hormone signals that help the body respond to food and blood sugar.
What changed with Onswik this week
As of September 30, 2026, the day this article was written, Onswik has U.S. clearance for blood sugar control in adults with type 2 diabetes. The FDA's licensing letter is signed September 23, 2026. Lilly's announcement followed on September 24. The indication includes diet and exercise alongside treatment.
Its full medicine name is insulin efsitora alfa-gobe. The FDA's summary, marked “Content current as of: 09/24/2026,” calls it the second weekly insulin cleared for adults with type 2 diabetes.
The practical change is about injection burden: roughly 52 basal injections a year instead of 365 with a daily basal insulin. That comparison counts background insulin only. A person who also needs mealtime insulin may still have several injections each day.
Weekly insulin versus a weekly GLP-1
Insulin helps move sugar from the blood into cells and limits how much sugar the liver releases. Type 2 diabetes develops when the body doesn't use insulin well or doesn't make enough.
GLP-1 is a gut hormone involved in insulin release and fullness. Semaglutide activates its receptor, the cell's receiving point for that signal. Tirzepatide also activates the receptor for GIP, another gut hormone involved in insulin release. Their insulin response is glucose-dependent: stronger when blood sugar is high, weaker as it falls.
| Medicine | Main role in this comparison |
|---|---|
| Onswik | Supplies long-acting background insulin |
| Semaglutide | Activates GLP-1 signaling; supports insulin release when glucose is elevated |
| Tirzepatide | Activates GLP-1 and GIP signaling; supports insulin release when glucose is elevated |
As of September 30, 2026, the day this article was written, the Mounjaro label reads “Revised: 8/2026.” The Ozempic label reads “Revised: 7/2026.” Both warn that combining treatment with insulin can increase low blood sugar risk. The guide to tirzepatide for type 2 diabetes explains its treatment role.
What the QWINT trials found
Four large QWINT trials studied more than 3,400 adults with type 2 diabetes. They included people starting insulin and people already using background insulin, sometimes with mealtime insulin.
A1C, also called HbA1c, is a blood test that estimates average blood sugar over roughly three months. The trials compared its change with weekly efsitora and daily basal insulin.
Two studies in adults who hadn't previously used insulin give a useful starting point:
| Trial | Participants and follow-up | Average A1C fall: weekly versus daily | Important or severe low blood sugar episodes per person-year |
|---|---|---|---|
| QWINT-1 | 795 adults; 52 weeks | 1.19 versus 1.16 percentage points, compared with glargine | 0.50 versus 0.88 |
| QWINT-2 | 928 adults; 52 weeks | 1.26 versus 1.17 percentage points, compared with degludec | 0.58 versus 0.45 |
These are the group averages reported in QWINT-1, New England Journal of Medicine, 2025, and QWINT-2, New England Journal of Medicine, 2024. Both met the test for noninferiority: weekly insulin stayed within a preset acceptable gap from daily insulin. QWINT-1 did not establish a better A1C result for weekly insulin.
The episode counts combine blood sugar readings below 54 mg/dL with severe lows requiring another person's help. A person-year means one person followed for one year. These rates count episodes, including repeat episodes, rather than the percentage of people affected.
The lower rate in QWINT-1 doesn't establish that weekly insulin always causes fewer lows. QWINT-2 reported a numerically higher rate with efsitora. Both were closely supervised trials, and everyone knew which insulin they received.
QWINT-2 also included people using GLP-1 medicines. Weekly insulin met its A1C comparison both with and without those medicines. That supports studying the treatments together; it doesn't make semaglutide and insulin interchangeable.
What fewer shots does not mean
Fewer injections do not remove hypoglycemia, the medical term for low blood sugar. Severe episodes can cause seizures or unconsciousness, can be life-threatening, or can cause death. Other listed reactions include injection-site problems, allergic reactions, itching, rash, swelling and weight gain.
As of September 30, 2026, the day this article was written, the Onswik prescribing information reads “Revised: 09/2026.” It describes weekly injections on the same day, with the dose individualized from blood sugar readings and treatment goals.
The label has separate starting plans for people new to insulin and people switching from daily insulin. Some plans use a larger one-time starting dose. Repeating that starting dose is specifically identified as a medication-error risk.
The label also warns about mix-ups with other insulin products or weekly diabetes injections. Its long action can delay recovery from a low. A prescriber sets the actual dose, any transition plan and the monitoring schedule.
Adding a GLP-1 medicine makes the medication list especially important. Tirzepatide and low blood sugar covers that combination question. A new approval is a reason for a treatment conversation, not a reason to stop or switch insulin independently.
Where compounded GLP-1 treatment fits
As of September 30, 2026, the day this article was written, Onswik's clearance concerns Lilly's branded insulin. It doesn't change the review status of a pharmacy-made tirzepatide or semaglutide preparation.
Tirzepatide and semaglutide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, which are different from an FDA-approved product: the formulations offered here are not FDA-approved. A compounded medication is prepared by a licensed pharmacy for an individual prescription. Results from branded-drug trials do not establish the exact response to that preparation.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and doctor. For someone using insulin, that conversation includes how the medicines fit together and who manages glucose-related changes.
What to watch next
As of September 30, 2026, the day this article was written, Lilly's September 24 announcement says the Onswik KwikPen will reach the U.S. “in the coming months.” It names two concentrations: 500 and 1,000 units/mL, meaning different amounts of insulin in each milliliter. It gives no specific launch day.
Availability and insurance coverage will shape the practical conversation. The clinical questions remain specific: recent glucose readings, previous lows, current insulin, other medicines and whether the weekly schedule fits. A clear plan also identifies the clinician responsible for dose changes and follow-up.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
